Participated · Series A · Sep 2025

Optain Health offers a portable robotic retinal camera, integrated AI workflows, and teleophthalmology to enable rapid, non‑invasive screening for eye diseases and systemic risk (oculomics). Its platform detects diabetic retinopathy, glaucoma, age‑related macular degeneration, and assesses cardiovascular risk while delivering teleophthalmology grading in the U.S. The company was co‑created in 2023 by Aegis Ventures and builds on more than a decade of Australian R&D led by Professor Mingguang He. Optain is expanding deployments into primary care, optometry, and health systems with the goal of closing care gaps and improving outcomes with minimal specialist staffing. The company uses teleophthalmology services in the U.S.; its automated disease detection software is not for sale in the U.S. Optain is scaling globally with investments in Australian R&D to support expansion outside the U.S. Optain develops AI-enabled software and hardware that noninvasively diagnose eye and systemic health conditions in real time using photos of the eye. Its portable retinal camera and accompanying AI software enable clinicians to screen for more than 140 eye and systemic conditions at early stages. The company is led by CEO Jeff Dunkel and positions the eye as a gateway to monitor whole-person health. Optain's approach is based on over a decade of research by Professor Mingguang He of the University of Melbourne and the Centre for Eye Research Australia. The company traces its roots to Australian-founded Eyetelligence (launched in 2019), whose clinically validated and regulatory-approved AI products are commercialized across Australia, New Zealand, Europe, Japan and the Middle East. Optain intends to use recent seed funding to expand operations and development efforts.

Participated · Equity · Oct 2023

Capital Rx operates a cloud-native pharmacy benefit management (PBM) platform that adjudicates prescription drug claims and provides price transparency to employers, insurers, and other payers. The company is now broadening its technology to handle medical claims as well, positioning itself as an end-to-end claims processor across both pharmacy and medical benefits. By unifying these workflows, Capital Rx aims to give payers better visibility into total healthcare spending and negotiate more favorable rates. Management says the fresh capital will accelerate product expansion and support additional hiring to meet customer demand. The firm reports an oversubscribed funding round and cites strong interest from new and existing investors. A spokesperson disclosed that Capital Rx now carries a $3.25 billion valuation, underscoring investor confidence in its growth trajectory. Although detailed revenue or user metrics were not provided, the company emphasized that the additional funds will enable it to scale its platform nationwide.

Participated · Series B · Sep 2021

Xealth is a Seattle-based company that develops digital health enablement solutions for health systems. Its platform allows providers to prescribe and monitor digital health content, apps, and services as easily as medications. The platform incorporates custom data and analytics so health systems can track, analyze, and evaluate digital health use through its integration platform. Led by CEO Mike McSherry, Xealth reports 12 million orders sent, 100,000 providers engaged, and three million patients reached to date. The company received an investment from Morningside Ventures and intends to use the funds to expand operations and its development efforts. The amount and instrument of the investment were not disclosed in the announcement. Xealth provides a platform that centralizes integration, prescribing, monitoring and governance for digital health tools within clinician workflows. The platform is tightly integrated with EHRs and has full integrations with the largest EHR vendors. It is available to more than 100,000 physicians and its deployments demonstrate a 50–80% reduction in integration and deployment costs while driving substantial patient engagement. Xealth is backed by health systems and strategic investors, including Cerner, Novartis, Philips, ResMed, McKesson Ventures, Threshold Ventures and LRV Health. The company plans to use the new funding to roughly double its team and to fund product innovation, including enhancements to its intelligence engine to better match tools to patients and scale deployments across the U.S. Spun out of Providence St. Joseph Health in 2017 and based in Seattle, Xealth has raised $52.6 million to date. Xealth provides a platform that enables health systems to organize, integrate, deploy and activate digital health tools and programs. Through the platform, clinicians can find and order digital health tools directly from the EHR workflow, send those digital orders to patients' smartphones or desktops, monitor patient engagement and analyze the effects of more engaged patients. The company raised an additional $3M in its Series A, bringing the round to $14M total, and intends to use the funds to advance development and deployment of its platform for digital health programs. Xealth spun out of Providence St. Joseph Health in 2017 and is led by CEO Mike McSherry; it is based in Seattle, Washington. It works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Duke Health and other leading health systems. Xealth is a digital prescribing platform that enables clinicians to integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Its platform supports patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce recommendations. Care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Originally incubated and spun out of Providence St. Joseph Health in 2017 and led by CEO Mike McSherry, the company is based in Seattle, WA. Xealth works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Baylor Scott and White, and Duke. The company raised $11m in a Series A to accelerate expansion of its platform. Xealth is launching a digital prescribing and analytics platform that lets physicians and clinicians prescribe and track educational health content, disease-management apps, and monitoring devices directly from their EMR charting interface. The platform aggregates and filters a variety of content sources into a care provider’s existing EMR workflow, simplifying creation of a customized patient experience. Clinicians can discuss digital tools during appointments, track patient usage afterward, and schedule reminders to encourage engagement. Patients access prescribed digital health tools through their health system’s secure patient portal. Xealth was founded in 2016 by Mike McSherry and was incubated within Providence’s Digital Innovation Group. The company has raised $8.5M to support launch and expansion with participating health systems planning broader integration and use of third-party digital solutions.